Currently, the screening of PCa is first based on physical examination of the prostate gland (digital rectal examination—DRE) together with the determination of PSA (prostate-specific antigen) in blood, which has allowed for better detection of this malignant disease and contributed to reducing mortality. This evidence concerns the gene KLK3 and posterior cortical atrophy.